These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27074937)

  • 61. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance.
    Park BH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    BJU Int; 2014 Jun; 113(6):864-70. PubMed ID: 24053308
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket.
    Brassetti A; Lombardo R; Emiliozzi P; Cardi A; Antonio V; Antonio I; Aldo S; Tommaso R; Alberto P; Gianluca D
    Urology; 2018 Jan; 111():129-135. PubMed ID: 29032238
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study].
    Léon P; Cancel-Tassin G; Koutlidis N; Calves J; Funes de la Vega M; Fournier G; Valeri A; Cormier L; Larré S; Cussenot O
    Prog Urol; 2017 Mar; 27(3):158-165. PubMed ID: 28258910
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pathological upgrading and upstaging at radical prostatectomy in Jamaican men with low-risk prostate cancer.
    Morrison BF; Aiken WD; Reid G; Mayhew R; Hanchard B
    Ecancermedicalscience; 2019; 13():971. PubMed ID: 31921342
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The clinical utility of prostate cancer heterogeneity using texture analysis of multiparametric MRI.
    Hameed M; Ganeshan B; Shur J; Mukherjee S; Afaq A; Batura D
    Int Urol Nephrol; 2019 May; 51(5):817-824. PubMed ID: 30929224
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predicting extracapsular involvement in prostate cancer through the tumor contact length and the apparent diffusion coefficient.
    Granja MF; Pedraza CM; Flórez DC; Romero JA; Palau MA; Aguirre DA
    Radiologia; 2017; 59(4):313-320. PubMed ID: 28473218
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prediction of Pathological Upgrading at Radical Prostatectomy in Prostate Cancer Eligible for Active Surveillance: A Texture Features and Machine Learning-Based Analysis of Apparent Diffusion Coefficient Maps.
    Xie J; Li B; Min X; Zhang P; Fan C; Li Q; Wang L
    Front Oncol; 2020; 10():604266. PubMed ID: 33614487
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Computer-aided classification of prostate cancer grade groups from MRI images using texture features and stacked sparse autoencoder.
    Abraham B; Nair MS
    Comput Med Imaging Graph; 2018 Nov; 69():60-68. PubMed ID: 30205334
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance.
    Jeong CW; Park YH; Hwang SI; Lee S; Jeong SJ; Hong SK; Byun SS; Lee HJ; Lee SE
    Prostate Int; 2014 Dec; 2(4):169-75. PubMed ID: 25599072
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identifying intermediate-risk candidates for active surveillance of prostate cancer.
    Savdie R; Aning J; So AI; Black PC; Gleave ME; Goldenberg SL
    Urol Oncol; 2017 Oct; 35(10):605.e1-605.e8. PubMed ID: 28736249
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Multiparametric magnetic resonance imaging markers of clinically significant prostate cancer].
    Goncharuk DA; Veliev EI; Loran OB; Paklina OV; Setdikova GR; Shabunin IV; Sokolov EA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2019 Aug; 27(Special Issue):559-564. PubMed ID: 31747147
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores.
    Abdel-Rahman O
    Future Oncol; 2018 Jun; 14(15):1469-1476. PubMed ID: 29745768
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hypointense hepatocellular carcinomas on apparent diffusion coefficient mapping: Pathological features and metastatic recurrence after hepatectomy.
    Mori Y; Tamai H; Shingaki N; Hayami S; Ueno M; Maeda Y; Moribata K; Deguchi H; Niwa T; Inoue I; Maekita T; Iguchi M; Kato J; Terada M; Yamaue H; Ichinose M
    Hepatol Res; 2016 Jun; 46(7):634-41. PubMed ID: 26407147
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intraprostatic locations of tumor foci of higher grade missed by diagnostic prostate biopsy among potential candidates for active surveillance.
    Kim K; Lee JK; Choe G; Hong SK
    Sci Rep; 2016 Nov; 6():36781. PubMed ID: 27827421
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System.
    Porcaro AB; Siracusano S; de Luyk N; Corsi P; Sebben M; Tafuri A; Mattevi D; Bizzotto L; Tamanini I; Cerruto MA; Martignoni G; Brunelli M; Artibani W
    Curr Urol; 2017 Aug; 10(3):118-125. PubMed ID: 28878593
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Younger Men With Prostate Cancer Have Lower Risk of Upgrading While on Active Surveillance: A Meta-analysis and Systematic Review of the Literature.
    Mahran A; Turk A; Buzzy C; Wang M; Yang J; Neudecker M; Jaeger I; Ponsky LE
    Urology; 2018 Nov; 121():11-18. PubMed ID: 30056194
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.
    Jazayeri SB; Kwon YS; McBride R; Leapman M; Collingwood S; Hobbs A; Samadi DB
    Curr Urol; 2017 Jul; 10(2):97-104. PubMed ID: 28785195
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer.
    Lee SH; Koo KC; Lee DH; Chung BH
    Prostate Int; 2015 Dec; 3(4):127-31. PubMed ID: 26779459
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Editorial comment.
    Labanaris AP
    J Urol; 2013 Mar; 189(3):866. PubMed ID: 23261235
    [No Abstract]   [Full Text] [Related]  

  • 80. [Usefulness of imaging studies in prostate cancer: Analysis of 241 patients].
    Martínez M N; Calvo C; Ibarra Á; Ramos C; Zambrano N
    Rev Med Chil; 2017 May; 145(5):579-584. PubMed ID: 28898333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.